StockMirror — Stock Screener

AMANTA Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Amanta Healthcare reported a strong Q2 FY27 with 17% YoY revenue growth to INR83.1 crore and 22% YoY EBITDA growth to INR18 crore, maintaining a healthy EBITDA margin of 21.6% despite raw material volatility . The company commissioned SteriPort Line 3, increasing capacity by ~75%, which is expected to ramp to full utilization by late November 2026 . A 10.8 MW captive solar plant is delivering structural cost savings of ~INR9 crore annually . The balance sheet has strengthened with debt/equity down to ~1.1x, and the company has a clear 2-year roadmap of 20%+ revenue CAGR and 25%+ EBITDA margins . The SVP facility, focused on inhalation and ophthalmic products, is expected to be commissioned in Q1 FY28 and is a key future growth driver, though management conservatively guides only INR16 crore revenue from it in FY28 . Key risks include polymer price volatility and regulatory timelines for product approvals. Overall, the earnings call conveyed a positive and confident outlook, backed by clear growth drivers and financial discipline.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management has a clear 2-year target of 20%+ revenue CAGR and 25%+ EBITDA margins . They are investing in capacity expansion (SteriPort, SVP) for growth, while simultaneously focusing on cost efficiencies (solar, automation) and product mix improvement to expand margins .

About Amanta Healthcare Limited

Amanta Healthcare Limited (AMANTA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More